Result: The most prevalent RT RAMs among children and adolescents and their relative proportions were as follows: M184V (76.6%, n = 49/64), K103N (45.3%, n = 29/64), Y181C/V/I (28.1%, n = 18/64), T215F/Y (25.0%, n = 16/64), V108I (18.8%, n = 12/64), A98G (15.6%, n = 10/64), G190A (12.5%, n = 8), K101E/H (12.5%, n = 8), M41L (10.9%, n = 7/64), L74I/V (10.9%, n = 7/64), and H221Y (10.9%, n = 7/64) (Figure 1a,b).
Result: The most prevalent RT RAMs in pregnant women were as follows: K10
Development of Human Immunodeficiency Virus Type 1 Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains.
PMID: 34516245
2021
Antimicrobial agents and chemotherapy
Abstract: A114S/M184V exhibited higher EFdA resistance (~24-fold) than either M184V (~8-fold) or A114S alone (~2-fold).
Abstract: A novel EFdA resistance mutational pattern that included A114S was identified in the background of M184V.
Abstract: Biochemical experiments confirmed decreases in the enzymatic efficiency (kcat/Km) of WT versus A114S (2.1-fold) and A114S/M184V/A502V (6.5-fold) RTs, with no effect of A502V on enzymatic efficiency or specific infectivity.
Abstract: Regardless of the starting viral sequence, all selected EFdA-resistant variants i
Transmitted drug resistance and transmission clusters among HIV-1 treatment-naive patients in Guangdong, China: a cross-sectional study.
Result: K103N (0.42%, 10/2368), Y181C (0.21%, 5/2368), and G190A (0.21%, 5/2368) were the most common NRTI-associated mutations, and M184V (0.21%, 5/2368), L210W (0.21%, 5/2368), and T215S (0.13%, 3/2368) were the most common NNRTI-associated mutations.
Discussion: The most frequent NRTI-associated mutations in our study were M184V and L210W, while they are M41L and D67G in Southwest China and T215C/D in Iceland and the south-central United States.
Phylogenetic and Drug-Resistance Analysis of HIV-1 Sequences From an Extensive Paediatric HIV-1 Outbreak in Larkana, Pakistan.
Result: The DRM RT:M184V was found in two sequences - both in cluster_CRF02_AG_1.
Table: M184V
Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding.
PMID: 34446677
2021
Journal of acquired immune deficiency syndromes (1999)
Abstract: We did not observe differences in probability of VF in people living with HIV with an M184V resistance mutation (P = 0.689); however, in a deeper analysis, M184V mutation was a predictor of VF (P = 0.038) in patients with time of virological suppression <88 months.
Distribution characteristics of drug resistance mutations of HIV CRF01_AE, CRF07_BC and CRF08_BC from patients under ART in Ganzhou, China.
PMID: 34402512
2021
The Journal of antimicrobial chemotherapy
Abstract: The most common DRMs of these three subtypes were K103N and M184V, while the mutation frequencies of M41L, D67N, K70R, K101E, V106M, Y181C, K219E, H221Y and N348I were obviously different among subtypes.
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
PMID: 34397746
2021
Journal of acquired immune deficiency syndromes (1999)
Result:
Result: Altogether, 68 participants with baseline NRTI resistance (including 50 with M184V/I) received B/F/TAF during the study and had postswitch virologic data.
Result: Among participants with M184V or I mutations at baseline 97% (30 of 31) on B/F/TAF and 95% (19 of 20) on SBR had HIV-1 RNA <50 copies/mL at week 24.
Result: At baseline, 13% (44 of 328) in the B/F/TAF group and 16% (26 of 165) in the SBR group had NRTI resistance, including 9% (31 of 328) and 12% (20 of 165) with M184V/I mutations in the B/F/TAF and SBR groups, respectively.
Result: One participant with M184V on B/F/TAF discontinued after the baseline visit and did not have virologic data at week 24.
Table: M184V/I
Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.
Abstract: Crystallography of HIV RTY115F/F116Y/Q151M/F160M/M184V, mimicking HBV RT L180M/M204V, showed that the F115 bulge (F88 in HBV RT) caused by the F160M mutation induced deviated binding of dCTP from its normal tight binding position.
Case Report: Emergent Resistance in a Treatment-Naive Person With Human Immunodeficiency Virus Under Bictegravir-Based Therapy.
PMID: 34189182
2021
Open forum infectious diseases
Abstract: We describe a case of treatment-emergent resistance to bictegravir in a person recently diagnosed with human immunodeficiency virus who developed M184V and R263K mutations while on therapy.
Discussion: Neither the M184V (RT) mutation nor the R263KR (INI) mutation was observed in the 2 pretreatment genotypes, suggesting that these were treatment-emergent mutations and were not transmitted or present at baseline.
Discussion: The M184V (RT) mutation was detected after 17 weeks of therapy, and at week 37 the R263KR (INI) mutation was detected via bulk sequencing (Viracor Lab, Missouri) necessitating a change in ART.
HIV mutation literature information.
PMID: 
2021
The Pan African medical journal
Browser Board
Co-occurred Entities
Filtrator
ViMRT